Previous 10 | Next 10 |
Baudax Bio recently reported their Q4/2020 earnings that revealed a huge miss on EPS and revenue. The COVID-19 headwinds continue to restrict Anjeso's ability to get off the launch pad. Despite the disappointing start, the company has several commercial highlights that investors shoul...
Baudax Bio, Inc. (BXRX) Q4 2020 Earnings Conference Call February 16, 2021 08:00 ET Company Participants Claudia Styslinger - Investor Relations Gerri Henwood - President and Chief Executive Officer John Harlow - Chief Commercial Officer Ryan Lake - Chief Financial Officer Conference Call Par...
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...
Baudax Bio (BXRX) shares were choppy during premarket trading after the company posted full-year results that missed Wall Street estimates, as the drug maker dealt with slow commercialization of its newly launched pain medication Anjesco, due to the disruptions caused by the COVID-19 pan...
Baudax Bio (BXRX): FY GAAP EPS of -$3.93 misses by $3.33.Revenue of $0.5M misses by $1.13M.Press Release For further details see: Baudax Bio EPS misses by $3.33, misses on revenue
Deepening Usage of ANJESO Evidenced by a Reorder Rate of 60% by the End of 2020 and 58% Growth in Vials Sold from the Sequential Quarter Secured Approximately $55 Million in Gross Proceeds from Equity Offerings Over the Past Four Months Management to Host Investor Confer...
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it will report full year 2020 financial results on Tuesd...
KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...
Baudax Bio ([[BXRX]] +6.6%) entered into a definitive agreement with institutional and accredited investors for the purchase and sale of an aggregate of 11M shares at $1.60/share in a registered direct offering.Offer closing expected to occur on or about Feb.10.Gross proceeds are expected to ...
MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it has entered into a definitive agreement with institut...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023